Boehringer Ingelheim International
Boehringer Ingelheim International is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
Neoadjuvant trastuzumab, pertuzumab and zongertinib without chemotherapy in HER2-positive breast cancer: the TRAIN-5 study
Sponsor Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Boehringer Ingelheim International?
The 2026-10-09 snapshot links Boehringer Ingelheim International to 1 distinct CTIS trials. Recorded services include Source of monetary support. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Boehringer Ingelheim International?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Boehringer Ingelheim International conducted?
The linked trials record locations in 1 country, including Netherlands. These are trial locations, not confirmed office locations or countries where Boehringer Ingelheim International delivered services.
What can this page tell me about Boehringer Ingelheim International's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Boehringer Ingelheim International. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Boehringer Ingelheim International GmbH